Skip to main content
Popular Press
Early Breast Cancer: 5 Years Versus 3 Years of Adjuvant Bisphosphonate Treatment
JNCCN 360 (2021)
  • Noelle L Cutter, Ph.D., Molloy College
Abstract
The optimal duration of treatment using bisphosphonate for patients with early breast cancer is still unclear. In the phase III SUCCESS trial, Thomas W.P. Friedl, PhD, and colleagues from University Hospital Ulm, Prittwitzstr, Ulm, Germany, found there was no statistically significant difference in survival outcomes between 5 and 2 years of adjuvant zoledronate treatment. Their results were reported in JAMA Oncology.
Publication Date
August 30, 2021
Citation Information
Noelle L Cutter. "Early Breast Cancer: 5 Years Versus 3 Years of Adjuvant Bisphosphonate Treatment" JNCCN 360 (2021)
Available at: http://works.bepress.com/noelle-cutter/72/